Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Finished Goods (2016 - 2025)

Vycor Medical has reported Finished Goods over the past 10 years, most recently at $103114.0 for Q4 2025.

  • Quarterly Finished Goods rose 5.15% to $103114.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $103114.0 through Dec 2025, up 5.15% year-over-year, with the annual reading at $103114.0 for FY2025, 5.15% up from the prior year.
  • Finished Goods was $103114.0 for Q4 2025 at Vycor Medical, down from $108569.0 in the prior quarter.
  • Over five years, Finished Goods peaked at $145909.0 in Q4 2023 and troughed at $97837.0 in Q2 2025.
  • The 5-year median for Finished Goods is $113316.0 (2025), against an average of $118795.8.
  • Year-over-year, Finished Goods rose 12.47% in 2021 and then tumbled 32.79% in 2024.
  • A 5-year view of Finished Goods shows it stood at $130355.0 in 2021, then increased by 6.62% to $138980.0 in 2022, then grew by 4.99% to $145909.0 in 2023, then tumbled by 32.79% to $98060.0 in 2024, then rose by 5.15% to $103114.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Finished Goods are $103114.0 (Q4 2025), $108569.0 (Q3 2025), and $97837.0 (Q2 2025).